Antimicrobial photodynamic therapy mediated by methylene blue in surfactant vehicle as adjuvant to periodontal treatment. Randomized, controlled, double-blind clinical trial

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.

The aim of this study was evaluated the photodynamic effect of methylene blue in sodium dodecyl sulfate in periodontitis.

Why It Was Studied

Sodium dodecyl sulfate is a surfactant that may control this aggregation.

Who Took Part

According to the abstract, 36 participants were involved.

36 participants with periodontitis were selected and allocated randomly in two group for intervention and other two for control - all of them were treated with scaling and root planing before aPDT.

Two sites of each participant were selected for the experimental procedures.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Three periodontal evaluations were done: at the selection time, at the day of intervention and thirty-day after this.

Pre-irradiation time was 1 min and 2 min for irradiation.

Laser (Therapy XT, DMC, São Carlos, Brazil) with wavelength of 660 nm and 100 mW of power was used.

Microbiological evaluations were performed to quantify microorganisms before and immediately after intervention.

Quantitative microbiological evaluation was the primary outcome; morphological aspects of bacterial colony, and clinical probing depth was the secondary one.

What Was Measured

The subject headings attached to it are Photochemotherapy, Photosensitizing Agents, Methylene Blue, Surface-Active Agents, Combined Modality Therapy, Sodium Dodecyl Sulfate and Periodontitis.

Author keywords: Antimicrobial photodynamic therapy, Antimicrobials, Laser therapy and Periodontal disease.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 36 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Photodiagnosis and photodynamic therapy), a journal based in Netherlands.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.